-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The centralized procurement of Chinese patent medicines is accelerating, and the centralized procurement of Chinese patent medicines in Hubei Alliance and Guangdong Alliance has been completed
.
Among them, the Hubei 19-province alliance of Chinese patent medicine centralized procurement announced the results of the proposed selection at the end of 2021.
97 companies and 111 products were selected, and the selected products fell by an average of 42.
27%; Guangdong 6-province alliance of Chinese patent medicine centralized procurement also announced not long ago.
/ Alternative results, 174 companies and 361 products are to be selected / alternative, with an average drop of 56%
.
Among them, 249 varieties are to be selected, with an average decrease of 64%; 112 varieties are to be selected, with an average decrease of 38%, and the overall price reduction is relatively mild
.
Judging from the centralized procurement of the two major Chinese patent medicine alliances led by Guangdong and Hubei, there are more than 100 Chinese patent medicine companies participating, with a wide range of influence
.
The industry believes that, on the whole, the special centralized procurement of proprietary Chinese medicines has officially entered the substantive start-up stage from the level of discussion and preparation
.
In the future, the centralized procurement of Chinese patent medicines has become the general trend
.
Under centralized procurement, although product price cuts will put pressure on enterprises, in the long run, the advantages outweigh the disadvantages, which is conducive to forcing Chinese patent medicine enterprises to innovate and upgrade, and work hard on research and development to optimize the collaborative innovation of quality, cost, and social awareness.
.
Analysts further pointed out that under the normalization of centralized procurement, the traditional promotion of pharmaceutical representatives is no longer feasible.
Enterprises need to make efforts in academic and branding, pay attention to top-level innovation, overall operation, and improve products, academics, customers, brands, new media, etc.
The overall operational capability makes the function, economy, society, medical expenses and other values of the product more prominent
.
In addition, some people in the industry believe that with the advancement of the centralized procurement of Chinese patent medicines and the trend of medical insurance cost control, there are great uncertainties in the market of Chinese patent medicine medical institutions.
new battlefield"
.
According to data from Minet.
com, it is estimated that the sales volume of Chinese patent medicines in urban physical pharmacies and online pharmacies in China will be close to 120 billion yuan in 2021, a year-on-year increase of 5.
2%, of which online pharmacies have grown.
50%
.
According to the data of the Minet database, in 2021E, there are nearly 200 Chinese patent medicines with sales of more than 100 million yuan in physical pharmacies in Chinese cities, with a cumulative sales scale of more than 60 billion yuan, a year-on-year increase of about 1.
9%
.
Among them, 95 are exclusive varieties (including exclusive dosage forms), with a total sales scale of more than 20 billion yuan, covering common diseases and chronic disease treatment fields such as respiratory diseases, cardiovascular and cerebrovascular diseases, and digestive system diseases
.
Among the 95 varieties, 63 are the 2021 National Medical Insurance Catalog, and 63 are OTC products
.
In terms of single-variety sales, the three varieties of Baiyunshan Chenliji Pharmaceutical Factory's Shujin Jianyao Pills, Nianci'an's Kyoto Nianci'an Milian Chuanbei Loquat Cream, and Yiling Pharmaceutical's Lianhua Qingwen Capsules will be released in 2021.
Sales have exceeded 1 billion yuan
.
In addition, the three varieties of Changyanning Tablets from Jiangxi Kangenbei Traditional Chinese Medicine, Pien Tze Huang from Zhangzhou Pien Tze Huang Pharmaceuticals, and Lanqin Oral Liquid from Yangzijiang Pharmaceuticals are also approaching the 1 billion mark
.
In addition, from the perspective of sales growth, 59 of the 95 varieties achieved a year-on-year increase in sales in 2021.
Among them, the sales of Yaoshen Cream from Chinese Medicine increased by more than 65% year-on-year, followed by Baiyunshan's Zishen Yutai Pill, Sanli Pharmaceutical's Kaihoujian Spray (children's type), Hopu Pharmaceutical's Xiaoer Xiaoji Zhike Oral Liquid, Jianmin Pharmaceutical's Longdu Zhuanggu Granules, etc.
, increased by over 40% respectively
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the Hubei 19-province alliance of Chinese patent medicine centralized procurement announced the results of the proposed selection at the end of 2021.
97 companies and 111 products were selected, and the selected products fell by an average of 42.
27%; Guangdong 6-province alliance of Chinese patent medicine centralized procurement also announced not long ago.
/ Alternative results, 174 companies and 361 products are to be selected / alternative, with an average drop of 56%
.
Among them, 249 varieties are to be selected, with an average decrease of 64%; 112 varieties are to be selected, with an average decrease of 38%, and the overall price reduction is relatively mild
.
Judging from the centralized procurement of the two major Chinese patent medicine alliances led by Guangdong and Hubei, there are more than 100 Chinese patent medicine companies participating, with a wide range of influence
.
The industry believes that, on the whole, the special centralized procurement of proprietary Chinese medicines has officially entered the substantive start-up stage from the level of discussion and preparation
.
In the future, the centralized procurement of Chinese patent medicines has become the general trend
.
Under centralized procurement, although product price cuts will put pressure on enterprises, in the long run, the advantages outweigh the disadvantages, which is conducive to forcing Chinese patent medicine enterprises to innovate and upgrade, and work hard on research and development to optimize the collaborative innovation of quality, cost, and social awareness.
.
Analysts further pointed out that under the normalization of centralized procurement, the traditional promotion of pharmaceutical representatives is no longer feasible.
Enterprises need to make efforts in academic and branding, pay attention to top-level innovation, overall operation, and improve products, academics, customers, brands, new media, etc.
The overall operational capability makes the function, economy, society, medical expenses and other values of the product more prominent
.
In addition, some people in the industry believe that with the advancement of the centralized procurement of Chinese patent medicines and the trend of medical insurance cost control, there are great uncertainties in the market of Chinese patent medicine medical institutions.
new battlefield"
.
According to data from Minet.
com, it is estimated that the sales volume of Chinese patent medicines in urban physical pharmacies and online pharmacies in China will be close to 120 billion yuan in 2021, a year-on-year increase of 5.
2%, of which online pharmacies have grown.
50%
.
According to the data of the Minet database, in 2021E, there are nearly 200 Chinese patent medicines with sales of more than 100 million yuan in physical pharmacies in Chinese cities, with a cumulative sales scale of more than 60 billion yuan, a year-on-year increase of about 1.
9%
.
Among them, 95 are exclusive varieties (including exclusive dosage forms), with a total sales scale of more than 20 billion yuan, covering common diseases and chronic disease treatment fields such as respiratory diseases, cardiovascular and cerebrovascular diseases, and digestive system diseases
.
Among the 95 varieties, 63 are the 2021 National Medical Insurance Catalog, and 63 are OTC products
.
In terms of single-variety sales, the three varieties of Baiyunshan Chenliji Pharmaceutical Factory's Shujin Jianyao Pills, Nianci'an's Kyoto Nianci'an Milian Chuanbei Loquat Cream, and Yiling Pharmaceutical's Lianhua Qingwen Capsules will be released in 2021.
Sales have exceeded 1 billion yuan
.
In addition, the three varieties of Changyanning Tablets from Jiangxi Kangenbei Traditional Chinese Medicine, Pien Tze Huang from Zhangzhou Pien Tze Huang Pharmaceuticals, and Lanqin Oral Liquid from Yangzijiang Pharmaceuticals are also approaching the 1 billion mark
.
In addition, from the perspective of sales growth, 59 of the 95 varieties achieved a year-on-year increase in sales in 2021.
Among them, the sales of Yaoshen Cream from Chinese Medicine increased by more than 65% year-on-year, followed by Baiyunshan's Zishen Yutai Pill, Sanli Pharmaceutical's Kaihoujian Spray (children's type), Hopu Pharmaceutical's Xiaoer Xiaoji Zhike Oral Liquid, Jianmin Pharmaceutical's Longdu Zhuanggu Granules, etc.
, increased by over 40% respectively
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
